TMEM106B and frontotemporal dementia: In the last decade, the role of TMEM106B as a disease modifier in FTD and other neurodegenerative disorders, especially those characterized by TDP-43 pathology, has been widely investigated, with variable and sometimes contradictory results (i.e., enhanced cognitive deterioration associated with the major rs1990622 risk allele in FTD patients).